Worst CTC grade of neutropenia during the first 2 years of TCZ treatment in sJIA and pcJIA patients by BW group.
| CTC Grade | sJIA | pcJIA | ||||
|---|---|---|---|---|---|---|
| All, N = 112 | BW < 30 kg, n = 58 | BW ≥ 30 kg, n = 54 | All, N = 188 | BW < 30 kg, n = 69 | BW ≥ 30 kg, n = 119 | |
| Grade 0–1, n (%), 1.5 × 109/l to normal | 50 (44.6) | 21 (36.2) | 29 (53.7) | 133 (70.7) | 49 (71.0) | 84 (70.6) |
| Grade 2, n (%), 1.0 to < 1.5 × 109/l | 34 (30.4) | 16 (27.6) | 18 (33.3) | 44 (23.4) | 13 (18.8) | 31 (26.1) |
| Grade 3, n (%), 0.5 to < 1.0 × 109/l | 26 (23.2) | 19 (32.8) | 7 (13.0) | 11 (5.9) | 7 (10.1) | 4 (3.4) |
| Grade 4, n (%), < 0.5 × 109/l | 2 (1.8) | 2 (3.4) | 0 | 0 | 0 | 0 |
Patients with sJIA weighing < 30 kg received TCZ 12 mg/kg every 2 weeks, and those weighing ≥ 30 kg received TCZ 8 mg/kg every 2 weeks. Patients with pcJIA weighing < 30 kg received TCZ 8 mg/kg or TCZ 10 mg/kg every 4 weeks, and those weighing ≥ 30 kg received TCZ 8 mg/kg every 4 weeks. BW: body weight; CTC: common toxicity criteria; pcJIA: polyarticular-course juvenile idiopathic arthritis; sJIA: systemic juvenile idiopathic arthritis; TCZ: tocilizumab.